{"id":153948,"date":"2026-11-01T12:31:10","date_gmt":"2026-11-01T12:31:10","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/153948\/"},"modified":"2026-11-01T12:31:10","modified_gmt":"2026-11-01T12:31:10","slug":"anthropics-ipo-filing-shows-how-its-boosting-biotech-research","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/153948\/","title":{"rendered":"Anthropic&#8217;s IPO Filing Shows How It&#8217;s Boosting Biotech Research"},"content":{"rendered":"<p>Anthropic conquered coding. Now it&#8217;s setting its sights on the human body.<\/p>\n<p><a target=\"_self\" class=\"\" href=\"https:\/\/www.businessinsider.com\/anthropic-s-1-filing-public-finances-compute-deals-2026-10\" data-track-click=\"{&quot;element_name&quot;:&quot;body_link&quot;,&quot;event&quot;:&quot;tout_click&quot;,&quot;index&quot;:&quot;bi_value_unassigned&quot;,&quot;product_field&quot;:&quot;bi_value_unassigned&quot;}\" rel=\"nofollow noopener\">Anthropic&#8217;s S-1 filing<\/a>, which outlines its ambitions and financials ahead of a massive initial public offering next month, reads as a life-sciences manifesto. The maker of Claude sees itself as a crucial cog in the next generation of biological and medicinal research \u2014 and is selling that lucrative vision to its would-be investors.<\/p>\n<p>Anthropic is hoping for a wave of new discoveries that will support its <a target=\"_self\" class=\"\" href=\"https:\/\/www.businessinsider.com\/anthropic-ipo-s1-cult-claude-religion-language-2026-10\" data-track-click=\"{&quot;element_name&quot;:&quot;body_link&quot;,&quot;event&quot;:&quot;tout_click&quot;,&quot;index&quot;:&quot;bi_value_unassigned&quot;,&quot;product_field&quot;:&quot;bi_value_unassigned&quot;}\" rel=\"nofollow noopener\">do-gooder mission<\/a> and convince the public of AI&#8217;s power and worth. Its life-science focus could also support financial growth beyond its AI <a target=\"_self\" class=\"\" href=\"https:\/\/www.businessinsider.com\/anthropic-katelyn-lesse-team-shifted-to-ai-coding-entirely-2026-10\" data-track-click=\"{&quot;element_name&quot;:&quot;body_link&quot;,&quot;event&quot;:&quot;tout_click&quot;,&quot;index&quot;:&quot;bi_value_unassigned&quot;,&quot;product_field&quot;:&quot;bi_value_unassigned&quot;}\" rel=\"nofollow noopener\">software engineering tools<\/a>. It would promote the use of Anthropic&#8217;s most advanced, expensive models in an industry already accustomed to spending billions on research and development.<\/p>\n<p>The S-1 filing is scattered with references to biotech ambition. Its second line says AI &#8220;could rapidly accelerate scientific innovation&#8221; and &#8220;bring cures for major diseases within reach.&#8221; A page later, biological progress tops the company&#8217;s list of ways it hopes AI will improve lives.<\/p>\n<p>Anthropic also references its life sciences business in its &#8220;growth strategy&#8221; section and writes that nine of the 10 largest pharmaceutical companies and eight of the 10 largest healthcare companies in the Fortune 500 spent at least $100,000 with Anthropic over a recent yearlong period.<\/p>\n<p>Read more about Anthropic&#8217;s S-1 filing<\/p>\n<p>&#8220;In the life sciences sector, where annual global pharmaceutical spend is expected to exceed $2 trillion in 2026, Claude is used in drug discovery and development by our customers, our biotechnology partners, and our own researchers,&#8221; the company writes in the filing.<\/p>\n<p>Anthropic declined to comment.<\/p>\n<p>Anthropic has begun investing in life sciences<\/p>\n<p id=\"16e6f599-bdf0-4921-a81b-761dcc0c51c9\">Anthropic has already gotten to work investing in life sciences. The company&#8217;s Claude Science product, which is in beta, came out in June. OpenAI, Anthropic&#8217;s erstwhile rival, has a competing offering dubbed Rosalind, while Google spinoff <a target=\"_self\" class=\"\" href=\"https:\/\/www.businessinsider.com\/isomorphic-labs-discover-cancer-beating-drugs-ai-max-jaderberg-google-2026-10\" data-track-click=\"{&quot;element_name&quot;:&quot;body_link&quot;,&quot;event&quot;:&quot;tout_click&quot;,&quot;index&quot;:&quot;bi_value_unassigned&quot;,&quot;product_field&quot;:&quot;bi_value_unassigned&quot;}\" rel=\"nofollow noopener\">Isomorphic Labs<\/a> plans to use AI to create cancer-beating drugs \u2014 promising a struggle between companies for research customers.<\/p>\n<p>Besides that, Anthropic started a molecular biology lab in the Bay Area this year and spent $400 million in stock in April to buy the biotech startup Coefficient Bio. Vas Narasimhan, the CEO of the pharmaceutical company Novartis, also joined Anthropic&#8217;s board in April. In August, Anthropic announced a new robotics standard that allows AI to control lab equipment. <\/p>\n<p>The company&#8217;s careers page shows it&#8217;s on a hiring spree for life sciences roles across chemistry, experimental biology, research engineering, and more. Two new roles opened late this week, offering $320,000 salaries to researchers capable of designing and manufacturing antibodies.<\/p>\n<p>                                Want more Business Insider in your news feed?<\/p>\n<p class=\"preferred-sources-module-desc body-xs\">\n                                  Add BI in Google so our reporting is easier to find when you\u2019re searching for what matters.\n                                <\/p>\n<p>In its S-1, Anthropic touted its work with pharma giant Lilly, saying the $1.3 trillion company has 50,000 employees with access to a Claude enterprise account and that more than 85% of its staff actively use the tool.<\/p>\n<p>CEO Dario Amodei is prioritizing life sciences<\/p>\n<p>Anthropic CEO Dario Amodei, a former theoretical physicist, has repeatedly touted AI&#8217;s potential in the life sciences as a reason to advance the tech&#8217;s capabilities.<\/p>\n<p>In a September essay about &#8220;pacing&#8221; AI research, Amodei said he had survived a cancer that wouldn&#8217;t have been treatable in the 1970s, and his father had died of a disease cured shortly after his death.<\/p>\n<p>He previously elaborated on the themes in a 2024 essay dubbed &#8220;Machines of Loving Grace.&#8221;<\/p>\n<p>&#8220;Biology is probably the area where scientific progress has the greatest potential to directly and unambiguously improve the quality of human life,&#8221; Amodei wrote, adding that he hopes AI-enabled research will help prevent and treat all infectious diseases, eliminate most cancers, and double the human lifespan.<\/p>\n<p>The general public is less optimistic. <a target=\"_self\" class=\"\" href=\"https:\/\/www.businessinsider.com\/anthropic-survey-reveals-ai-potential-impact-on-unemployment-2026-10\" data-track-click=\"{&quot;element_name&quot;:&quot;body_link&quot;,&quot;event&quot;:&quot;tout_click&quot;,&quot;index&quot;:&quot;bi_value_unassigned&quot;,&quot;product_field&quot;:&quot;bi_value_unassigned&quot;}\" rel=\"nofollow noopener\">Anthropic recently published survey results<\/a> from August, finding that 91% of staff think AI will make a Nobel-level discovery by 2030, compared with 39% of US adults. No AI-designed drugs have ever received FDA approval.<\/p>\n<p>Ben Mann, the co-leader of <a target=\"_self\" class=\"\" href=\"https:\/\/www.businessinsider.com\/anthropic-labs-team-ai-innovation-ipo-2026-9\" data-track-click=\"{&quot;element_name&quot;:&quot;body_link&quot;,&quot;event&quot;:&quot;tout_click&quot;,&quot;index&quot;:&quot;bi_value_unassigned&quot;,&quot;product_field&quot;:&quot;bi_value_unassigned&quot;}\" rel=\"nofollow noopener\">Anthropic&#8217;s Labs organization<\/a>, which builds new products and created Claude Code, told Business Insider this August that his small team is also focusing more on life sciences.<\/p>\n<p>&#8220;Labs itself has shifted its focus from sort of more standard software engineering things to things like what Dario has described as curing all diseases like, Machines of Loving Grace-style,&#8221; Mann said.<\/p>\n<p>Have a tip? Contact this reporter via email at <a target=\"_blank\" href=\"https:\/\/www.businessinsider.com\/mailto:scouncil@businessinsider.com\" data-track-click=\"{&quot;click_type&quot;:&quot;other&quot;,&quot;element_name&quot;:&quot;body_link&quot;,&quot;event&quot;:&quot;outbound_click&quot;}\" rel=\" nofollow noopener\">scouncil@businessinsider.com<\/a>, or over text, Signal, Telegram, or WhatsApp at 415-757-8198. Use a personal email address, a non-work WiFi network, and a non-work device;\u00a0<a target=\"_self\" href=\"https:\/\/www.businessinsider.com\/insider-guide-to-securely-sharing-whistleblower-information-about-powerful-institutions-2021-10\" data-track-click=\"{&quot;element_name&quot;:&quot;body_link&quot;,&quot;event&quot;:&quot;tout_click&quot;,&quot;index&quot;:&quot;bi_value_unassigned&quot;,&quot;product_field&quot;:&quot;bi_value_unassigned&quot;}\" rel=\"nofollow noopener\">here&#8217;s our guide<\/a>\u00a0to sharing information securely.<\/p>\n","protected":false},"excerpt":{"rendered":"Anthropic conquered coding. Now it&#8217;s setting its sights on the human body. Anthropic&#8217;s S-1 filing, which outlines its&hellip;\n","protected":false},"author":2,"featured_media":153949,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[2252,7801,30045,13063,42613,72184,59151,1124,5849,2115,14592,72185,64157,206,72183,49576],"class_list":["post-153948","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-ai","tag-anthropic","tag-april","tag-august","tag-bay-area","tag-ben-mann","tag-claude","tag-company","tag-customer","tag-development","tag-disease","tag-experimental-biology","tag-life-science","tag-novartis","tag-s-1-filing","tag-staff"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117541200991597531","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/153948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=153948"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/153948\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/153949"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=153948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=153948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=153948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}